Opioid growth factor arrests the progression of clinical disease and spinal cord pathology in established...

Area of Science:

• Neuroscience
• Immunology
• Pharmacology

Background:

• Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
• Experimental autoimmune encephalomyelitis (EAE) is a widely used mouse model for studying MS.
• Opioid growth factor (OGF), an endogenous neuropeptide, has shown therapeutic potential in various conditions.

Purpose of the Study:

• To investigate the efficacy of OGF in halting the progression of established EAE in mice.
• To evaluate the neuropathological effects of OGF treatment on EAE.
• To assess the role of the OGF-OGFr axis in EAE pathogenesis and OGF's potential as a biotherapy for MS.

Main Methods:

• Mice with established EAE were treated daily with OGF (10mg/kg) or saline for 40 days.
• Behavioral scores were monitored to assess disease progression and severity.
• Neuropathological analyses were performed to evaluate demyelination, neuronal damage, astrocyte activation, and T cell proliferation.

Main Results:

• OGF treatment significantly reduced EAE behavioral scores by 45% within 6 days compared to saline controls.
• Mice treated with OGF exhibited attenuated clinical signs, primarily limp tails and wobbly gait, versus paralysis in saline-treated mice.
• OGF inhibited T cell proliferation, reduced activated astrocytes and damaged neurons, decreased demyelination, and normalized aberrant pain sensitivity.

Conclusions:

• OGF effectively halts the progression of established EAE in a mouse model.
• OGF treatment demonstrates significant neuroprotective and immunomodulatory effects in EAE.
• The findings support the OGF-OGFr axis's role in EAE and OGF's potential as a safe and effective biotherapy for MS.